BackAtyr Pharma Overview

Atyr Pharma Receivables

Atyr Pharma's receivables is $430K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$426000.00
↓ 14.46% YoYΔ $-72000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Atyr Pharma Receivables History

Loading

Atyr Pharma vs. peers: Receivables Comparison

Loading

Atyr Pharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Atyr Pharma (ATYR) FAQ

As of the most recent data (June 2026), ATYR shows a receivables of $430K. That compares with $500K in the prior-year period — down 14.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ATYR's receivables is now $430K (was $500K) — a 14.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Atyr Pharma is outperforming or lagging.

Tracking ATYR's receivables over time shows whether Atyr Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $430K That compares with $500K in the prior-year period — down 14.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Atyr Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $430K) with ownership activity and broader fundamentals.

Atyr Pharma's receivables is $430K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.